DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2022–0016]

Grant of Interim Extension of the Term of U.S. Patent No. 9,364,354; Reducer®

AGENCY: United States Patent and Trademark Office, Department of Commerce.

ACTION: Notice of Interim Patent Term Extension.

SUMMARY: The United States Patent and Trademark Office has issued an order granting interim extension for a one-year interim extension of the term of U.S. Patent No. 9,364,354.

FOR FURTHER INFORMATION CONTACT: Ali Salimi by telephone at (571) 272–0909; by mail marked to his attention and addressed to the Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 22313–1450; by fax marked to his attention at (571) 273–0909; or by email to ali.salimi@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to one year if the regulatory review is anticipated to extend beyond the expiration date of the patent.

On April 8, 2022, Neovasc Medical Ltd., the patent owner of record, timely filed an application under 35 U.S.C. 156(d)(5) for a third interim extension of the term of U.S. Patent No. 9,364,354. The patent claims the catheter implantable device, Reducer®. The application for patent term extension indicates that a Premarket Approval Application (PMA) P190035 was submitted to the Food and Drug Administration (FDA) on December 31, 2019. Review of the patent term extension application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because there is a reasonable expectation that the regulatory review period will continue beyond the twice-extended expiration date of the patent, June 6, 2022, a third interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate.

A third interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 9,364,354 is granted for a period of one year from the twice-extended expiration date of the patent.

Robert Bahr, Deputy Commissioner for Patents, United States Patent and Trademark Office.

The Commodity Futures Trading Commission (Commission) is publishing this notice to announce the renewal of the Market Risk Advisory Committee (MRAC). The Commission has determined that the renewal of the MRAC is necessary and in the public’s interest, and the Commission has consulted with the General Services Administration’s Committee Management Secretariat regarding the MRAC’s renewal.

SUMMARY: The Commodity Futures Trading Commission (Commission) is publishing this notice to announce the renewal of the Market Risk Advisory Committee (MRAC). The Commission has determined that the renewal of the MRAC is necessary and in the public’s interest, and the Commission has consulted with the General Services Administration’s Committee Management Secretariat regarding the MRAC’s renewal.

FOR FURTHER INFORMATION CONTACT: Alicia Lewis, MRAC Designated Federal Officer, at 202–418–5962 or alicia.lewis@cftc.gov.

SUPPLEMENTARY INFORMATION: In support of the Commission’s mission of promoting the integrity, resilience, and vibrancy of the U.S. derivatives markets through sound regulation as well as the monitoring and management of systemic risk, the MRAC’s objectives and scope of activities are to conduct public meetings, advise, and submit reports and recommendations to the Commission on: (1) Systemic issues that impact the stability of the derivatives markets and other related financial markets; and (2) the impact and implications of the evolving market structure of the derivatives markets and other related financial markets. The MRAC will operate for two years from the date of renewal unless the Commission directs that the MRAC terminate on an earlier date. A copy of the renewal charter will be posted on the Commission’s website at www.cftc.gov.

The DoD is publishing this notice to announce that it is renewing the Defense Innovation Board (DIB).

SUMMARY: The DoD is publishing this notice to announce that it is renewing the Defense Innovation Board (DIB).

FOR FURTHER INFORMATION CONTACT: Jim Freeman, DoD Advisory Committee Management Officer, 703–692–5952.

SUPPLEMENTARY INFORMATION: The DIB is being renewed in accordance with the Federal Advisory Committee Act (FACA) (5 U.S.C., appendix) and 41 CFR 102–3.50(d). The charter and contact information for the DIB’s Designated Federal Officer (DFO) are found at https://www.facadatabase.gov/FACA/apex/FACAPublicAgencyNavigation. The DIB provides the Secretary of Defense and Deputy Secretary of Defense with independent advice and recommendations to address challenges and accelerate innovation adoption into the culture, technologies, organizational structures, processes, and functions of the DoD. The DIB shall focus on innovative means to address future challenges and accelerate innovation adoption into the culture, technologies, organizational structures, processes, and any other topics raised by the Secretary of Defense or the Deputy Secretary of Defense (“the DoD Appointing Authority”) or the Under Secretary of Defense for Research and Engineering (USD(R&E)) unless otherwise provided for by statute or Presidential directive. The DIB is composed of no more than 20 members must possess some or all of the following: (a) A proven track record of sound judgment in leading or governing large, complex private sector corporations or organizations; (b) demonstrated performance in identifying and adopting new technology innovations into the operations of large organizations in either the public or private sector; (c) demonstrated performance in